Tumor‐Derived CDC37 Inhibits Antigen Cross‐Presentation in Dendritic Cells and Impairs Anti‐Tumor Immunity in Breast Cancer
Open Access
- 10 November 2025
- journal article
- Published by Wiley in Advanced Science
- Vol. 13 (5) , e06518
Abstract
Tumor mutational burden (TMB), usually representing high immunogenicity, cannot always predict treatment response of immune checkpoint blockade (ICB). Here, it is showed that defective antigen cross‐presentation in type 1 conventional dendritic cells (cDC1) is responsible for lacking tumor‐specific cytotoxic T lymphocytes (CTLs) in triple‐negative breast cancer (TNBC) patients. Mechanistically, tumor cytosolic CDC37, shuttled via extracellular vesicles (EVs) into the endosomes of intratumor dendritic cells (DCs), inhibits antigen cross‐presentation by locking antigen binding to HSP90 and precluding their translocation from endosomes to cytoplasm. CDC37 knockdown in tumor cells or inhibiting CDC37/HSP90 interaction in DCs efficiently promotes antigen translocation and enhances their cross‐presentation, which improves ICB therapeutic responses. Clinically, high tumor CDC37 expression is associated with low infiltration of antigen‐specific CTLs and poor ICB efficacy in TNBC patients. Therefore, tumor EV‐shuttled CDC37 locks antigen/chaperone interaction and impairs antigen cross‐presentation in DCs. Moreover, targeting CDC37 is promising to enhance anti‐tumor immunity and reverse ICB resistance.Keywords
Funding Information
- National Natural Science Foundation of China (82488101)
- National Natural Science Foundation of China (82330056)
- National Natural Science Foundation of China (92159303)
- National Natural Science Foundation of China (82222029)
- National Natural Science Foundation of China (82102865)
- National Natural Science Foundation of China (82572107)
- National Key Research and Development Program of China (2021YFA1300602)
- Science and Technology Planning Project of Guangdong Province (2023B1212060013)
This publication has 103 references indexed in Scilit:
- From mechanism to therapy: How EIPA modulates dendritic cell-mediated allergic responses via IL-12b and TIM4Biomedicine & Pharmacotherapy, 2025
- Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinomaCancer Cell, 2024
- Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistanceCancer Cell, 2021
- The Challenges of Tumor Mutational Burden as an Immunotherapy BiomarkerCancer Cell, 2020
- Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevoAnnals of Oncology, 2020
- Critical Role for CD103+/CD141+ Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in MelanomaCancer Cell, 2016
- Human natural killer cells promote cross‐presentation of tumor cell‐derived antigens by dendritic cellsInternational Journal of Cancer, 2014
- Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune ResponsesCancer Cell, 2014
- Marginating Dendritic Cells of the Tumor Microenvironment Cross-Present Tumor Antigens and Stably Engage Tumor-Specific T CellsCancer Cell, 2012
- Topical TLR9 agonists induce more efficient cross‐presentation of injected protein antigen than parenteral TLR9 agonists doEuropean Journal of Immunology, 2007